Georgia Sypsa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Georgia Sypsa has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anastasia N. Mavrogiannaki
Second Department of Internal Medicine and Diabetes Centre, NIMTS Hospital, 11521 Athens, Greece
2 shared publications - Christos Chologkitas
First Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, Agiou Thoma 17, 11526 Athens, Greece
2 shared publications - Dimitra Pavlopoulou
First Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, Agiou Thoma 17, 11526 Athens, Greece
2 shared publications - Dimitrios S. Karagiannakis
Fourth Department of Internal Medicine Attiko University Hospital, Medical School, National and Kapodistrian University of Athens Athens Greece
2 shared publications - Evangelos Cholongitas
First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, General Hospital Laiko, 115 27 Athens, Greece
2 shared publications - George V. Papatheodoridis
1(st) Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece
2 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 257
Evaluation of Sarcopenic Obesity in Patients with MASLD
Background/Obejctives: Sarcopenic obesity (SO) has gained growing attention in metabolic dysfunction-associated steatotic liver disease (MASLD), yet data in Caucasian populations remain limited. The aim of this study was to assess the prevalence of SO using different definitions and to explore its relationship with steroid androgens, physical performance and frailty in MASLD individuals. Methods: Two hundred Caucasian patients with MASLD and available dual-energy X-ray absorptiometry (DEXA) data were evaluated. Clinical, biochemical, hormonal and elastography data were recorded, while physical performance was assessed using the Short Physical Performance Battery (SPPB) and Liver Frailty Index (LFI). Results: SO prevalence ranged from 34.5% to 76.5% depending on the definition applied (AIMSO score, body mass index, and body fat percentage-based criteria). Across definitions, SO individuals showed greater hepatic steatosis, more metabolic comorbidities and demonstrated poorer physical performance. Lower dehydroepiandrosterone sulfate (DHEAS) levels were independently associated with SO when the definition is based on total body fat percentage, and waist circumference (WC) was consistently linked to SO across all definitions. Separate analysis based on gender, confirmed that DHEAS was independently associated with SO in men, while WC represented an independent factor associated with SO in both genders. Conclusions: In conclusion, SO is common among Caucasian MASLD patients and is accompanied by metabolic, hepatic, hormonal, and functional alterations. These findings may help recognize patients at risk of SO and support more focused assessment and monitoring in clinical practice.
- 15 May 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 257
Open AccessEvaluation of Sarcopenic Obesity in Patients with MASLD
Background/Obejctives: Sarcopenic obesity (SO) has gained growing attention in metabolic dysfunction-associated steatotic liver disease (MASLD), yet data in Caucasian populations remain limited. The aim of this study was to assess the prevalence of SO using different definitions and to explore its relationship with steroid androgens, physical performance and frailty in MASLD individuals. Methods: Two hundred Caucasian patients with MASLD and available dual-energy X-ray absorptiometry (DEXA) data were evaluated. Clinical, biochemical, hormonal and elastography data were recorded, while physical performance was assessed using the Short Physical Performance Battery (SPPB) and Liver Frailty Index (LFI). Results: SO prevalence ranged from 34.5% to 76.5% depending on the definition applied (AIMSO score, body mass index, and body fat percentage-based criteria). Across definitions, SO individuals showed greater hepatic steatosis, more metabolic comorbidities and demonstrated poorer physical performance. Lower dehydroepiandrosterone sulfate (DHEAS) levels were independently associated with SO when the definition is based on total body fat percentage, and waist circumference (WC) was consistently linked to SO across all definitions. Separate analysis based on gender, confirmed that DHEAS was independently associated with SO in men, while WC represented an independent factor associated with SO in both genders. Conclusions: In conclusion, SO is common among Caucasian MASLD patients and is accompanied by metabolic, hepatic, hormonal, and functional alterations. These findings may help recognize patients at risk of SO and support more focused assessment and monitoring in clinical practice.
- Open Access
- 5 February 2026
- Published by MDPI AG in Preprints.org
Evaluation of Sarcopenic Obesity in Patients with MASLD
Sarcopenic obesity (SO) has gained growing attention in metabolic dysfunction-associated steatotic liver disease (MASLD), yet data in Caucasian populations remain limited. The aim of the study was to assess the prevalence of SO using different definitions and to explore its relationship with steroid androgens, physical performance and frailty in MASLD individuals. Two hundred Caucasian patients with MASLD and available dual-energy X-ray absorptiometry (DEXA) data were evaluated. Clinical, biochemical, hormonal and elastography data were recorded, while physical performance was assessed using the Short Physical Performance Battery (SPPB) and Liver Frailty Index (LFI). SO prevalence ranged from 34.5% to 76.5% based on different SO definitions. SO individuals showed greater hepatic steatosis, more metabolic comorbidities and demonstrated poorer physical performance. Lower dehydroepiandrosterone sulfate (DHEAS) levels were independently associated with SO when definition is based on total body fat percentage, and waist circumference (WC) was consistently linked to SO across all definitions. Separate analysis based on gender, confirmed DHEAS being independently associated with SO in men, while WC represented an independent SO predictor in both genders. In conclusion, SO is common among Caucasian MASLD patients and is accompanied by metabolic, hepatic, hormonal, and functional alterations, highlighting the need for better identification in clinical practice.
- 5 February 2026
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of Sarcopenic Obesity in Patients with MASLD
Sarcopenic obesity (SO) has gained growing attention in metabolic dysfunction-associated steatotic liver disease (MASLD), yet data in Caucasian populations remain limited. The aim of the study was to assess the prevalence of SO using different definitions and to explore its relationship with steroid androgens, physical performance and frailty in MASLD individuals. Two hundred Caucasian patients with MASLD and available dual-energy X-ray absorptiometry (DEXA) data were evaluated. Clinical, biochemical, hormonal and elastography data were recorded, while physical performance was assessed using the Short Physical Performance Battery (SPPB) and Liver Frailty Index (LFI). SO prevalence ranged from 34.5% to 76.5% based on different SO definitions. SO individuals showed greater hepatic steatosis, more metabolic comorbidities and demonstrated poorer physical performance. Lower dehydroepiandrosterone sulfate (DHEAS) levels were independently associated with SO when definition is based on total body fat percentage, and waist circumference (WC) was consistently linked to SO across all definitions. Separate analysis based on gender, confirmed DHEAS being independently associated with SO in men, while WC represented an independent SO predictor in both genders. In conclusion, SO is common among Caucasian MASLD patients and is accompanied by metabolic, hepatic, hormonal, and functional alterations, highlighting the need for better identification in clinical practice.